Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
November 9, 2023
Earnings Call Speaker Segments
Salli Schwartz
executiveHello, everyone, and thanks for being with us on this call about our third-quarter 2023 results. During the session today, we'll review the financial figures we published after the market closed, then share some thoughts on what's happening across our commercial and regulatory work, and we'll wrap up by taking your questions. Our earnings release is available on the Investor Relations section of Illumina.com. Joining us from Illumina are Jacob Thaysen, our Chief Executive Officer, and Joydeep Goswami, our Chief Financial Officer and Chief Strategy and Corporate Development Officer. Jacob will speak about where Illumina's business currently stands, and Joydeep will take you through the financial results, which include GRAIL. Before we begin, I want to note that the European Commission's interim directives — which barred us from completing the GRAIL purchase under EU merger rules — require GRAIL to remain a distinct, independently run entity, apart from Illumina. Please be aware that this call is being taped, and a recording of the audio will be kept in the Investor area of our site. We intend for any statements about our financial performance and business activity that look ahead, made on today's call, to receive protection under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements carry risks and uncertainties. What actually happens or what we actually achieve could differ significantly from what is anticipated or covered here. Every forward-looking statement reflects information we have right now, and Illumina takes on no duty to revise any of them later. For a fuller picture of the risks and uncertainties that might make real outcomes come out differently, please look at the filings Illumina submits to the Securities and Exchange Commission — among them Illumina's latest Forms 10-Q and 10-K. Having said that, I'll hand things over to Jacob.
Jacob Thaysen
executiveThanks, Sally. Hello everyone, and I appreciate you being on the call today. As all of you are aware, a bit more than 6 weeks have passed since I stepped into the CEO position at Illumina. Leading this organization is a privilege. Before coming to Illumina, I spent over 10 years at Agilent, where I was in charge of the Diagnostic and Genomics Group, and most recently, Agilent's biggest business, the Life Science and Applied Markets Group. For a long time, I have respected Illumina for the part it played in creating the genomics market, and being here is tremendously exciting for me. In my initial weeks, I made it a priority to get to know the people who work here and to sit down with a number of our customers. Illumina's team is extremely talented, and their passion and dedication to what we do has made a strong impression on me. Our staff and our customers alike are motivated to advance genomics. Just like our team, I care deeply about genomics and what this field can contribute to healthcare and personalized medicine, especially within oncology. This represents an enormous opportunity, and Illumina will stay the central player, even while others come into the market. The infrastructure Illumina has established across 25 years, our strong offerings that establish the worldwide benchmark, and our profound dedication to future innovation will keep driving genomics and multiomics adoption globally. Now to our Q3 results; during the third quarter, Illumina brought in revenue of roughly $1.12 billion, unchanged from the prior year, or a 1% increase in constant currency terms. That outcome was disappointing. The macro environment is still difficult for our sector and for our customers, and customers are growing more hesitant and restricted when making purchase decisions. Even though gross margin declined compared with last year, disciplined control of our operating expenses enabled us to achieve diluted non-GAAP EPS of $0.33, which was also roughly unchanged from a year ago. Although the external environment is beyond our control, Illumina's management team and I stay dedicated to helping our customers and to executing operationally. As part of my thorough assessment of the business, I am taking another look at our strategic initiatives along with our goals for long-term revenue growth and operating margins. We will share our updated targets with you later in the coming year. One of my main priorities is to obtain clarity regarding the GRAIL situation. So I have asked, and the Board has formed, a special committee to speed up decisions concerning GRAIL. In addition, we have brought in advisors and are getting ready for sale and capital markets transactions. We anticipate filing a Form-10 confidentially with the SEC. After that, we will reach out to third parties as sources of investment capital or as possible buyers while our appeals continue. I realize there have been questions about our appeals. Those appeals concern more than just GRAIL. They give Illumina flexibility for any divestiture of GRAIL as well as for transactions in the future. The appeals will not hinder our capacity to act quickly. Let me be clear, my focus is on the core business, and I will discuss that further following Joydeep's comments. Joydeep?
Joydeep Goswami
executiveThanks, Jacob. To begin, I'll go over our consolidated financial results, then walk through segment results for Core Illumina and GRAIL, and finish with my comments on how we see 2023 shaping up. My discussion will cover non-GAAP results, which factor in stock-based compensation. Please take a look at the GAAP reconciliation of those non-GAAP measures; it's included in today's release and in the supplementary data posted on our website. As Jacob mentioned, consolidated revenue for the third quarter came to $1.12 billion, which was flat compared with a year ago and rose 1% in constant currency terms. Versus the second quarter of 2023, consolidated revenue declined 5%. We had correctly expected high-throughput consumables revenue to fall sequentially because of the NovaSeq X transition, yet our placements of NovaSeq X instruments came in below what we anticipated during the quarter, since purchase constraints on the part of customers stretched out sales cycles. Non-GAAP net income reached $52 million, or $0.33 per diluted share, and that figure reflected dilution from GRAIL's non-GAAP operating loss, which was $155 million for the quarter. Even with lower revenue, non-GAAP EPS came in above our expectations, largely because we kept executing on expense reduction initiatives and because gross margin was higher than we had forecast. GAAP net loss totaled $754 million, or $4.77 per diluted share, and that included goodwill and intangible impairments of $821 million tied to the GRAIL segment. Those impairments stemmed mainly from a decline in Illumina's consolidated market capitalization and from a higher discount rate applied to the fair value cancellation of the GRAIL segment. Our non-GAAP tax rate for the quarter was 39.7%, down from 43.2% in Q3 2022, and both periods reflected the impact of R&D capitalization requirements. The decline from a year ago was mainly attributable to a reduction in non-GAAP tax expense, plus the impact of R&D capitalization requirements given increased amortization of capitalized R&D expenses. For the quarter, our non-GAAP weighted average diluted share count was roughly 158 million. Turning to segment results: Core Illumina revenue was $1.11 billion, flat year-over-year on both a reported and a constant currency basis, and it included anticipated reductions of about seven percentage points from two main categories. First, the drop in COVID surveillance along with the effect of sanctions in Russia, which together account for roughly 3.5 percentage points, and second, the year-over-year reduction in China revenue, which is also approximately 3.5 percentage points. COVID surveillance added about $4 million in total revenue in Q3 2023, versus $28 million in Q3 2022. Core Illumina sequencing consumables revenue was $695 million, a 4% decrease year-over-year. That decline was driven mainly by a 12% drop in sales to research customers; these customers felt the impact of the NovaSeq X transition and are cutting back on NovaSeq 6000 consumables purchases before their activity on NovaSeq X has fully ramped up. Total sequencing consumables revenue was also affected by the COVID, Russia and China factors I mentioned earlier, along with the impact of macroeconomic conditions on customers' purchasing power and project planning. Clinical customer sales provided some offset to the research pullback, as clinical sequencing consumables rose 10% compared with a year earlier, carried by ongoing strength in oncology and genetic disease testing. Now looking at sequencing activity: gigabase output across connected high- and mid-throughput machines was up 5% versus Q2 2023 and 29% compared with the prior year. We feel good about what we're seeing among both research and clinical high-throughput users who have a NovaSeq X in place. As anticipated, those users are posting stronger growth in sequencing output overall than high-throughput users who haven't yet moved to the NovaSeq X, whether measured quarter over quarter or year over year. To repeat, we view this data as a helpful gauge of broad activity patterns within our installed base, and it tends to track directionally with revenue over time. Core Illumina sequencing instruments revenue reached $179 million, an increase of 10% compared with a year earlier, mostly on the strength of NovaSeq X, which outweighed the drop in NovaSeq 6000 shipments. Gains in high-throughput instruments were partly countered by the anticipated mid-throughput decline tied to rising capital purchase and cash flow constraints that keep weighing on our customers' buying decisions around the world, plus local competition in China. On NovaSeq X, we finished Q3 with over 310 orders booked since launch. We shipped 97 NovaSeq X instruments during Q3, lifting our cumulative installed base to 273. Core Illumina sequencing service and other revenue came in at $142 million, rising 15% versus a year ago, mainly from greater instrument service contract revenue on a larger installed base and higher lab services revenue. Turning to Core Illumina's regional performance, every region is still dealing with two main challenges. First, tighter funding and budget pressure weighing on customers' purchasing power and project planning; second, high-throughput customers shifting to NovaSeq X and cutting back on NovaSeq 6000 consumables before their activity on NovaSeq X has fully ramped. Americas revenue hit $650 million, up 10% from a year earlier, on NovaSeq X placements and clinical testing volume that lifted consumables revenue. Clinical sequencing consumables shipments climbed over 20% versus the prior year. Europe revenue was $260 million, unchanged from a year earlier, or 1% higher in constant currency terms. Sequencing consumables growth came from mid-teens clinical growth and solid mid-throughput consumables, offset by lower COVID surveillance and unfavorable exchange rates. On sequencing instruments, high-throughput gains from NovaSeq X placements were outweighed by a mid-throughput instrument decline. India revenue totaled $98 million, falling 22% from a year earlier, or 19% in constant currency, which included an 11 percentage point hit from sanctions on Russia. The year-over-year drop also reflected weakness in Japan from the macroeconomic factors I noted earlier, along with the anticipated COVID surveillance slowdown. In Greater China, we brought in $98 million, which was down 26% from a year ago, or 25% when you strip out currency effects. That reflects the macroeconomic and geopolitical headwinds that keep persisting, plus competition locally in mid-throughput. Now on to the remaining Core Illumina P&L lines. Core Illumina non-GAAP gross margin came in at 66%, a drop of 290 basis points versus a year ago. The main reasons were product mix and reduced fixed cost leverage given lower manufacturing volumes, along with weaker instrument margins and increased field service and installation costs tied to the NovaSeq X launch, which is normal during a launch year. Core Illumina non-GAAP operating expenses were $481 million, which is $33 million less than a year ago and came in below what we expected, largely because of ongoing expense reduction efforts. Given all of that, Core Illumina non-GAAP operating margin landed at 22.5% in Q3 2023, versus 22.6% in Q3 2022. Even with the gross margin decline, operating margin stayed roughly flat compared to a year ago thanks to our proactive cost management work. Turning now to GRAIL's financial results: GRAIL revenue for the quarter reached $21 million, up 110% from a year ago, mostly on the strength of Galleri adoption. GRAIL non-GAAP operating expenses came to $161 million, rising $12 million versus a year ago, mostly from efforts to scale up GRAIL's commercial and R&D organizations. Shifting to consolidated cash flow and balance sheet items: operations provided $139 million in cash. Capital expenditures for the third quarter of 2023 were $45 million, and free cash flow was $94 million.
Joydeep Goswami
executiveNo shares of common stock were bought back by us during the quarter. Cash, cash equivalents, and short-term investments totaled roughly $933 million at the close of the quarter. In Q3 2023, $750 million in cash was deployed by the company to settle the outstanding principal on convertible notes that came due in August 2023. Turning to 2023 guidance: consolidated revenue for the full year 2023 is now projected by us to fall 2% to 3% versus 2022, with Core Illumina revenue declining 3% to 4% year-over-year. Keep in mind these ranges incorporate expected reductions of roughly 200 basis points from COVID surveillance, about 100 basis points of impact on our business from sanctions in Russia, declines in our China business, plus a negative year-over-year foreign exchange effect. GRAIL revenue for 2023 is now anticipated to land at the low end of the $90 million to $110 million range. For fiscal 2023, Core Illumina sequencing instrument revenue is now expected by us to drop 5% to 6% year-over-year, pushed by capital and cash flow constraints that keep affecting how our customers purchase globally, along with the decline in our China business. The reduction versus our earlier guidance stems mainly from lower NovaSeq X shipment expectations for 2023. Our forecast now is to ship 330 to 340 NovaSeq X instruments this year, since customers' purchasing constraints are stretching out sale cycles. Core Illumina sequencing consumables revenue is also now expected by us to fall 5% to 6% year-over-year, driven chiefly by lower NovaSeq 6000 consumables as customers move to NovaSeq X. Macroeconomic conditions are weighing on customer project planning and budgets, along with the effect of sanctions in Russia, the slowdown in COVID surveillance, and the decline in our China business. The drop from our prior guidance mainly reflects a slower ramp in NovaSeq X consumables, partly because of our lower placement expectations, plus the growing impacts of macroeconomic constraints; Core Illumina total sequencing revenue is now expected by us to decline 3% to 4% year-over-year. This still includes intercompany sales to GRAIL of approximately $30 million, eliminated in consolidation. Consolidated non-GAAP operating margin is now expected by us at 4% to 4.5%, and Core Illumina non-GAAP operating margin at 19% to 19.5%. Our revised operating margins reflect lower revenue expectations for the year, partly offset by continued expense reduction initiatives. Our non-GAAP tax rate for 2023 is now expected to be approximately 39%, owing to a discrete tax benefit recognized in Q3 2023 related to prior year return adjustments. Finally, non-GAAP earnings per diluted share for 2023 are now expected by us in the range of $0.60 to $0.70, reflecting non-GAAP diluted shares outstanding of approximately 159 million shares. Dilution from GRAIL's non-GAAP operating loss is now expected at approximately $660 million, as GRAIL continues managing its expense base in line with its latest revenue outlook. I'll now hand it back to Jacob for his closing remarks. I appreciate that.
Jacob Thaysen
executivePrior to starting the Q&A portion, I'd like to restate how dedicated Illumina is to standing behind our customers during this challenging macroeconomic climate. External forces are beyond our power to influence, but we can refine what we ourselves do so that we make it through this stretch successfully and put the company in position to resume faster growth once conditions improve. I'm aware many of you want to know what we're thinking about 2024. Since 2023 isn't over yet, we're still working through our 2024 budget — that's the caveat here. Our preliminary take is that 2024 will end up looking quite close to 2023. We aren't anticipating any near-term easing in the macro backdrop, and geopolitical challenges have remained persistent; still, we take encouragement from early indicators around NovaSeq X utilization, and as the X keeps rolling out, we're positioned strongly for the consumables ramp and broader growth once market conditions get better. This situation is obviously fluid, and we'd like the chance to build out our thinking thoroughly. So for 2024, no guidance will be given until our Q4 earnings call in February. My decision to come to Illumina stemmed largely from my deep belief in what the Core Illumina business can become. Over the next month, I'll keep listening and learning, but I'll also be concentrating on a handful of critical priorities. Number one, we have to push our top line as hard as we can given this environment; that translates into ongoing placements of NovaSeq X along with every one of our instruments, which sets the stage for stronger consumables demand. We'll keep collaborating closely with customers globally, whether they're bringing new instruments into their workflows, kicking off new projects, or developing new tests or assays. Number two, we must sustain innovation sharply aligned with what matters most to our customers. Such innovations encompass automation and sample-to-answer solutions, which help reinforce our leading position globally. Simultaneously, our R&D spending needs to be handled with discipline and rigor. We just introduced our 25B Rating Kit. Customers had been eagerly awaiting it, and it will unlock the complete capability of the NovaSeq X. Number three, we must sharpen our operational excellence across geographies, functions, and processes. Earlier this year, we shared a plan aimed at lowering our analyzed run rate expenses. Our team has delivered, managing to cut analyzed run rate expenses by roughly $175 million, surpassing our earlier target of more than $100 million; these savings will keep providing flexibility for additional investment in high-growth areas as well as supporting our margins. I'm determined to carry out each of these priorities with a powerful sense of urgency. Our attention is on achieving concrete gains that underpin profitable long-term growth for Illumina and for our shareholders. At this point I'll ask the operator to open the line for Q&A.
Vijay Kumar
analystHi everyone, I appreciate you letting me ask something, and Jacob, glad to have you at Illumina. Perhaps my main question concerns GRAIL, and it might have two parts. As I understand it, the divestiture order from the EC called for 2.5 years of cash outlay. Given where GRAIL's OpEx spending stands right now, what does that actually mean? Does it amount to $1.75 billion in cash outlay? And on a related note, I noticed you put out an announcement about a special committee. Which people sit on that special committee? What will this committee be focused on? Are there any further specifics? It came across as somewhat different, and I simply want to grasp what makes it different, what exactly has changed?
Jacob Thaysen
executiveYes, Vijay, many thanks, and I'm truly thrilled to be joining Illumina here, and allow me to take your second question first, after which I'll bring Joydeep in as well to speak to what those 2.5 years signify, but as I mentioned here, when I arrived at the company, I believed it was crucial to obtain clarity regarding GRAIL, and it mattered greatly to me to have the board's backing and to act quickly in order to move things forward, and because of that, we set up a special committee made up of three board members, and then, apart from me, that committee is chaired by me. So there are three board members along with me who will collaborate with the management team and genuinely go through every element surrounding the divestiture order so we can be sure we're able to reach some quick decisions. We have to decide which route we will take. Will it be a trade sale, the spin, the split, with no sponsor, and naturally, there are numerous considerations tied to that; that is truly what the special committee is assisting me and the remainder of the management team in doing. Joydeep.
Joydeep Goswami
executiveYeah, Vijay. Hey, regarding that 2.5 years of cash support, or for GRAIL, we're continuing to talk with the European Commission about what that actually translates to as a specific figure. So I'm not able to share those specifics. We'll return with that once we've reached alignment, but I think, as Jacob mentioned, this isn't something we need to fund entirely by ourselves. Now that we've collaborated with the EC to produce a divestiture order that matches our expectations for flexibility, we have a number of options, even if a spin or a split decision occurs. We could bring in a sponsor who can cover all or a portion of what's needed for the 2.5 years of cash support, or we could turn to the markets and raise that money too. So keep watching for updates on that one.
Dan Brennan
analystHi, appreciate your willingness to answer our questions. Jacob, glad to have you aboard. This will probably be our final one since that's all the time we've got, though it's really two questions in one. First, Jacob, you obviously departed a terrific position at Agilent to join this company, so we'd certainly like to hear your perspective on Illumina's growth rate and outlook whenever you're prepared to share it. I'd also like to hear your perspective on the NGS market as a whole and on your new role — specifically, what kinds of growth traits do you consider sensible for that space? With the price reductions, there's considerable uncertainty around how elastic demand really is. So my first question covers the broader NGS market, if you have a take on it. Second, I wanted to ask about the X in particular. I realize you're reducing the placement figure because of customer limitations, but could you share anything about current orders or backlog? And the last piece is about guidance. Dan, you've seen Illumina lower its outlook multiple times. Many other companies in the space are dealing with the same problem, but yours has stretched out longer than most. So I'm curious what adjustments could be made to improve how guidance is set, ideally removing the chance of further cuts down the road — thanks.
Jacob Thaysen
executiveThanks, Dan. I'd say Joydeep will also weigh in on a few of those points, but let me begin with what I've seen since arriving at Illumina — both as an outsider looking in and now from inside — which is that this core business holds enormous potential. From my perspective, there are plenty of chances within NGS markets, and I believe we've clearly come out the other side of a difficult stretch at present. The entire life science tools sector appears to be experiencing this, and at Illumina, we certainly aren't shielded from it either. Still, when it comes to growth rates, I'll be dedicating time going forward to continue learning the business and truly getting to know how the organization operates. Right now, I can't yet give you a definitive view on the growth rates this business should target or the commitments we'll make. What I can promise is that I'll return at some point later in '24 and lay all of it out once the time is right. Until then, my read is that the broader market looks quite strong, and Illumina will have plenty of chances to expand from here. I'd also add that as I've absorbed what's coming out of the organization and taken a close look at our innovation engine and the shape of our roadmaps, I've grown genuinely enthusiastic about what lies ahead for this company. I believe we'll keep breaking new ground here. So when it comes to guidance, and now that Joydeep has joined the team, what we really wanted to accomplish was making sure that as we give signals, especially about '24, we're being cautious right now in how we frame our — it's not official guidance yet, but at least how we look at '24, because we simply aren't observing any change, any short-term change, in the economic environment, and so we felt it was important to step forward now and then share what we're seeing, although Joydeep, would you like to?
Joydeep Goswami
executiveNo, I believe that's accurate, Jacob. Regarding the guidance aspect, look, we promised you we'd return with whatever perspective we have on the macroeconomic conditions, and I believe we've honored that promise. Actually, we might have acted somewhat like the canary in the coal mine by indicating some of this to you earlier, particularly during this year compared to others, correct? One factor, naturally, that you mentioned involves the prolonged, sort of absence of growth or the diminished growth we've experienced. That's accurate. I think part of what struck us simultaneously with the macroeconomic decline is the shift, a significant shift involving our platform, which has affected us as customers transition from the 6,000 to the X, yet there's a delay between when they deplete some of their inventory on the X and then wait to completely ramp up on the X; so you'll observe that eventually balance out. We have no uncertainty about that; and then, regarding the X, I want to stress again, and I think you'll have noticed this from your channel checks too, demand and enthusiasm for the innovation and the capabilities that the X delivers stay robust. I think we're extremely thrilled about the introduction of the 25B and I think those among you who went to ASHE would have observed our customers' enthusiasm for that and the data emerging from the other 25B and the enhancements we keep making to the software genuinely connect with our customers. So we stay quite engaged with that.
Puneet Souda
analystHello, Jacob. It's good to have you joining us. I'd like to ask something with two parts — regarding the 25B launch, could you share some detail on how, and perhaps Joydeep can chime in here, the transformation is likely to play out over roughly the next two months. Of course, the 25B brings a higher price, but not all customers will really be in a position to fill that flow cell. So you'll see some back-and-forth to a degree. Maybe you could address that qualitatively for the near term. And then a broader topic: competition. Jacob, you've been watching what's happening with LCMS companies and other firms operating in China. So what's your vision there — for Illumina specifically, given that one of the bigger rivals is based over there? Longer term, how do you see Illumina's standing in that market? And if I can squeeze in one more on competition: a customer of yours in diagnostics — one doing NIPT and MRD work — mentioned they're in the process of validating multiple platforms. So what's your read on the competitive landscape? Thanks.
Jacob Thaysen
executiveThank you so much, Puneet — and I'm genuinely glad to be part of this. I'll start with what you asked about China. You're right that I do bring direct experience from having led operations there. I know China well and understand what it takes to run operations in that market. What sets Illumina apart from certain other life science tools firms is that we face a local rival whose sequencing technology is at least adequate. Still, China matters enormously to us. At present, we're executing a "in China, for China" approach so that we'll be far better situated there down the road. We're making a real commitment to that country, and I believe we can achieve strong results there. A lot of our clients in China would rather partner with Illumina because of what we represent — our quality, and the fact that we're the top brand in the market. So our position in China is going to stay very solid. On the topic of competition in general, you're correct — there are competitors in the space. As you're aware, I know quite well what it's like to operate in a highly competitive landscape, and I believe what Illumina brings to the table, which should benefit us tremendously, is a powerful brand and a substantial installed base. Nearly every paper that gets published relies on what we've built, and beyond that, naturally, there's what I observe inside the company — the plans we've laid out for the products we'll roll out next, plus our ability to innovate — all of which should keep us in an exceptionally strong position within this marketplace. That said, I certainly recognize, and I'm completely clear-eyed about the fact, that going forward the competition is going to be intense. In the end, my view is that this just forces us to stay laser-focused on the people we serve, and we'll do everything we possibly can for them. So I'm here, and I'm ready to fight for it.
Joydeep Goswami
executiveOkay, perhaps I can add something here. Let me begin with the competitive landscape. As Jacob mentioned, we certainly treat it as important, while also keeping a very close watch on it worldwide based on what we observe in the field. So I would say that beyond China, both the competition and our share have come in as we anticipated. Naturally, when new players enter a market, you'll see some modest share erosion, yet outside China it has largely matched our expectations. Regarding 25B, Puneet, let me first note that what we've observed here are early signals: when we examine sequencing activity growth measured in gigabases, we find that customers who have adopted DX are experiencing a quicker rate of increase in output and sequencing output compared with those who haven't adopted DX — so that's an encouraging indication that X is in fact driving additional sequencing activity among these customers. And once again, it remains quite early. They're building up, fully validating on their specific workflows. With 25B, I believe you're correct. It will drive even greater capacity and more experiments; we've heard from customers interested in running very large single-cell experiments, for instance, who are quite enthusiastic about 25B and what it enables. So we anticipate that will unfold. I think when you consider the dynamics of whether you're operating full flow cells or not, there's a highly intricate interplay of factors that will produce higher prices per gigabase until your flow cells are fully loaded. So we can discuss that separately, but we do expect those dynamics to closely resemble what you saw when NovaSeq 6000 was introduced, along with some of the other S4 flow cells, and so on.
Jacob Thaysen
executiveYet, Joydeep, I'd add one more point to wrap up regarding the chance we've identified: the clients I've personally encountered in the clinical field are genuinely enthusiastic about the new flow cell, since it unlocks assays, products, and offerings they never previously had access to. Naturally, they'll need some time to validate everything and become operational, but we're seeing a lot of them at this moment hurrying to be the first out with it.
Dan Arias
analystYeah, hi everyone, thanks for taking the question. Jacob, building on what was said about the special committee that's going to review GRAIL, what's the rough schedule they're likely to follow before they arrive at a decision, and could you also bring us up to date on when the GRAIL team currently anticipates a readout from the NHS gallery study — thank you.
Jacob Thaysen
executiveYeah, what I can share is that we're moving as fast as possible within the framework to evaluate the options available; and I'll say, I share the frustration all of you feel, and I'm eager to put this matter behind us. So we're operating on extremely tight timelines. Right now, I'd rather not make any commitment, since I need to be certain I can fulfill whatever I promise regarding any timeline; incidentally, I'd also like to let you know that this morning we received feedback from the ECGA that a date has now been set for the hearing, an oral hearing, scheduled for mid-December. So that's encouraging in the sense that things are now progressing. And on that point, the appeals matter to us, clearly because of GRAIL, but perhaps equally because they help ensure we retain flexibility for future transactions we may pursue and, clearly, we can also eliminate the finance and so forth. That's the reason the appeals remain important.
Joydeep Goswami
executiveWhen it comes to the timing for NHS' GRAIL readout, my understanding is that, just as GRAIL previously indicated, the ultimate expectation there is at some point in 2024, and a preliminary readout will also come before that, or a full readout as well.
Michael Ryskin
analystThanks a lot for fielding this, and it's good to be on the board. I'd like to build on what was asked before regarding the demand sitting underneath the market, and what makes you confident about the longer-term picture; let me frame it around the guidance revision you just gave for the third quarter. You point to several of the same macro pressures other companies have mentioned — what's happening in China, wider funding worries, and tightening budgets — and you say those things are holding back consumables spending; yet at the same time, the shift toward NovaX isn't showing up, because if you look at the order book, bookings have hardly increased from 2Q to 3Q. The figure moved from 260 up to 310; that means a 50-unit gain during the quarter, while you shipped 97. So it doesn't look like there's a huge wave of demand building for NovaX, and yet the Nova 6000 consumable appears to be decelerating sharply. I'm trying to square those two things: if customers aren't running sequences on the Nova 6000 because they're preparing for the Nova X, then you'd expect to see those orders rise. So how do you say with confidence that part of this reflects an instrument transition rather than simply weaker demand beneath the market?
Jacob Thaysen
executiveYes, let me begin once more by reiterating that demand does exist within the market space. We also noted overall that we're observing higher gigabase growth rates. So we clearly see plenty of activity out there, and once again, there's no question that over the long term this market looks quite healthy. What you're witnessing, I believe, is us moving through a very difficult environment that everyone else is also facing. And I think everyone last year, when they issued guidance, was likely hopeful that things would contract again in the second half, and everyone was caught off guard, or at minimum it didn't happen. As a result, we are being somewhat more cautious right now in how we project ahead. So that's one piece of it, but when it comes to the details, I think Joydeep can offer a bit more insight.
Joydeep Goswami
executiveAlright, so when we examine this, there are a few factors behind why the deceleration is being hit harder by the transition, correct? Of course, Michael, the broader macro pullback plays a role in this. However, regarding the transition, I can point to two specific things. We took a close look at high throughput customers — comparing those who bought an X against those who haven't — and it's clear the pullback in 6K consumables is far sharper among the ones who own an X. That gives us a solid control method for separating the transition's effect from wider macroeconomic patterns. And keep in mind, for a lot of these early adopters — really the heavier users, the higher output users on NovaSeq X — they are still in the process of ramping up with the X and the 25B. So that shift is going to show up, along with the ramp in X consumables, particularly once the 25B launches, though getting to full capacity after validating their workflows will require a few months for them.
Tejas Savant
analystHi everyone, good evening, and Jacob, glad to have you at Illumina. There are a few things I wanted to ask you. To begin with GRAIL, it seems you anticipate the ECJ ruling around the middle of 2024. Could you take us through what that means regarding what the committee is actually able to accomplish before that point, and then past the continuing litigation and determining whether and how to shed this asset, what's your approach to capturing the data value contained in GRAIL? Is that something the board and this committee are actively debating? And the last piece of what I'm asking is bigger picture on Core Illumina. Where do things stand with the important leadership positions? Do you believe you've got a stable team at this point, or might we see major changes over the coming months? Thank you.
Jacob Thaysen
executiveAll right, I'll begin with GRAIL and, as I've said previously — which is the reason I established the committee, a special committee — we face the European divestiture order, and clearly, even as the appeals continue, we'll pursue every avenue available to act as fast as we can. I also noted in my remarks that once the Form 10 is filed, we'll reach out and begin conversations with prospective buyers and so forth. We're also exploring the spin and similar options; so we're proceeding as rapidly as possible under that structure and we'll push forward, yes, once more, we'll push forward to the fullest extent we can here; so nothing truly is stopping us, since the appeals proceed simultaneously. So nothing stands in the way of us proceeding as rapidly as possible under that structure. On that note, regarding how GRAIL might be monetized, I'm not sure — Joydeep, do you have any perspective on that?
Joydeep Goswami
executiveMy sense is that this largely concerns the GRAIL data you're referring to. So that's certainly one possibility the committee is going to weigh, and that we as a team will weigh too, though it truly hinges on which divestiture path gets picked and on whatever we settle on through our discussions with the European Commission; so yes, it's definitely among the items under consideration as part of the different possibilities that Jacob said the committee intends to raise.
Jacob Thaysen
executiveRight, so regarding that final question, which I believe concerned the leadership group — let me answer it in a wider sense by saying that during the coming stretch I'll be carrying out a thorough review of the business. Once again, my time here amounts to 40 days, and the team, along with the skilled individuals throughout this organization, has genuinely impressed me. Naturally, though, as we proceed here in '24, I'll keep all of you informed about where my thinking stands.
Dan Leonard
analystThanks, and hi, Jacob. Since you're now moving toward what might be a more hand-to-mouth pattern of demand for the X, and with so little backlog remaining, I was hoping you could say more about how the pipeline appears and share any metrics available. Also, could you put a number on how much longer the sales cycle is getting? Has it become twice as long as before? Or is it some other multiple? Anything at all that would help us put that in context.
Jacob Thaysen
executiveDan, once again, I'd like to ask Joydeep to come in and give a bit more perspective on our current situation, though broadly I can say the sales cycle has stretched considerably compared with how things were previously. That's partly because reaching a decision takes time, and partly because it must work its way through every layer, where far more scrutiny now applies at each stage of decision making, and that's what we've observed. We notice it at Illumina, yet I believe this is something occurring across the industry generally; but Joydeep, would you like to add a little more?
Joydeep Goswami
executiveI'd like to back up what you said there, Jacob, and confirm it — we're still seeing a lot of enthusiasm for the X, and clearly the 25D launch has given that even more of a boost. On top of that, the pipeline keeps holding hundreds of opportunities, correct. So a shrinking pipeline isn't something we're dealing with; we keep adding opportunities into it. What's proven somewhat harder for us, given where the macroeconomy stands, is turning those pipeline opportunities into orders at the pace we'd envisioned. That's the sales cycle extension you brought up, and our expectation is that this will persist for us as well as for others for some additional time going forward here, right, until macroeconomic conditions come back, but there's no question they aren't — it isn't the case that demand is moving over to a different technology or a different instrument. It remains heavily concentrated on the X, and we keep talking with our customers to bring them along, and after they've made the purchase, to genuinely ramp them up and get them ramped as fast as we can so the consumables get pulled through as fast as we can.
Jacob Thaysen
executiveRight, and once more, like Joydeep mentioned, our pipeline is in good shape. As proof that things are progressing, within just the past few days we got 10 units of — what was it — 10 instrument orders for our X from one of our largest customers. So we're certainly noticing that customers genuinely are fond of the X and can truly see how it can be put to excellent use.
Joydeep Goswami
executiveOkay Jacob, you raise something worth noting there. What we're looking at is an order to grow the fleet. They've already worked with the X, and now they're going even bigger, correct?
Sung Ji Nam
analystHello, and thank you for fielding our questions. Jacob, welcome aboard. I have one quick item regarding GRAIL — what would you say is the main factor behind the guidance, with the revised outlook now sitting at the lower boundary of the earlier range? Thanks.
Jacob Thaysen
executiveI'm happy to take that one. So, once more, there are essentially a pair of factors at play. During this specific year, they encountered certain difficulties tied to their PDX revenue — that's the revenue from pharma services — and in addition, gallery sales, even though they are expanding at a healthy pace, came in below what they had originally anticipated, correct? So those two items have both had an effect.
Joydeep Goswami
executiveEven so, that's solid growth.
Jacob Thaysen
executiveActually, extremely solid growth. What we're observing there is roughly 100%.
Kyle Mikson
analystHi there, thanks. Glad to have you aboard, Jacob. I've got two things to ask. The first concerns GRAIL, and the second concerns Core. Regarding the funding for GRAIL alongside the divestiture, should this be a capital market transaction, the company will require 2.5 years of cash. I believe that point came up before. You might deliver that through an equity raise or by issuing debt. Could you walk us through precisely which options you have for generating that capital without doing an equity or debt offering? Then, regarding the Core business, you folks referenced the initial view for 2024. Is that somewhat comparable to 2023? Does it imply revenue will be flat year over year for a third consecutive year, and then perhaps you could comment on orders and placements for next year? For instance, might placements grow in 2024? Thank you.
Jacob Thaysen
executiveYes, so I'll begin with the second question, and once more, we will release the complete guidance during our Q4 '23 call in February, but I'm only giving you the initial view we currently hold for 2024, and given the macroeconomic environment, we want to — and we aren't seeing that shift at this moment. Should it shift at some point in 2024, clearly, we'd witness more momentum in the business, but I thought it mattered to share with everyone now how we view the year. There's more detail underlying it, but we're still working through the remainder of this year. And we're still finalizing the 2000 and, naturally, the 2024 budget as well. So it's too soon for me to share specifics about the year, but what I can say, as we've mentioned previously, is that we continue to have a strong pipeline on X in particular, and we expect — and we're simply observing that the sales cycle is taking longer than we anticipated, but you should in fact see that consumables are beginning to pick up in 2024 as well.
Joydeep Goswami
executiveRegarding GRAIL, as I believe I said before, we now have multiple paths available that could assist in covering what's needed for the 2.5 years of funding. Take a spin, for instance — there's a sponsored spin possibility in which a sponsor might contribute a significant portion, or perhaps the entire amount, of the capital that's needed. Another route leans more toward a capital markets transaction, essentially a split-style approach where you'd go raise money for GRAIL through capital markets and through an IPO market for GRAIL. So we're examining and working our way through these different paths. Naturally, they hinge on particular market conditions as well as interest in GRAIL coming from private placement. We'll keep you updated as we head out to the market and weigh those paths.
Catherine Schulte
analystHi everyone, I appreciate the questions, and Jacob, welcome aboard. I suppose regarding what you said about '24 — when you mention that results could end up resembling '23 — in that scenario, how should we think about Core Illumina operating margins? Would they too come in around the same as '23, or, considering some of the cost cuts you've mentioned, is there potential for upside there?
Jacob Thaysen
executiveYes, thank you for raising that. My view is that at present Illumina possesses an excellent model, honestly. Our operating gross margins are quite robust, I'd say. Clearly, when growth comes, we're able to drive that down to the bottom line as well, yet in a flat setting, and naturally we're finding that more difficult. So at this moment, on both the top line and the bottom line, we anticipate staying flat.
Joydeep Goswami
executiveYeah, and I think you've got a point. We're anticipating gross margins will get better in the coming year, clearly as more zeroables get blended in. Regarding the cost cuts we've implemented during this year, I just want to remind everyone that a substantial chunk of those savings was already captured this year. So as we move forward, they won't add incrementally to next year. And then working against those two favorable items, we do anticipate that variable compensation, along with the rationalization and the year-over-year comparison on that, will chip away at the gains you've had, and that's combined with merit increases and inflation, correct? So, and once more, we didn't pay executives stock-based compensation or variable compensation this year, since our performance hasn't been up to par; so we do anticipate that will return in the next year as we fix some of that.
Jacob Thaysen
executiveOn that point, though, from everything I'm looking at, as I said, the company's gross margins are also solid, yet there's plenty we can do to keep making them better. So nothing I see, at least for someone like me just arriving here, suggests the thesis has changed regarding Illumina returning to the margins it has posted historically; and we'll be working toward that. In the past, I think the thinking has been that this comes about through growth, and obviously we need growth to fuel part of it, but going forward we'll also place real emphasis on operational excellence to build that.
Conor McNamara
analystHey everyone, I appreciate you taking my question, and Jacob, glad to have you in San Diego. So, based on what you've mentioned regarding 2024, going from where things stood before the pandemic in 2019 through to 2024, that suggests roughly a 5% yearly growth rate for the core business, which is pretty much consistent with the broader life science tools market, even though your company has always put around 20% of sales into R&D. So, as someone investing in Illumina, should I view this as a story of EBIT margin expansion going forward, where you cut R&D to match what peers do, or do you believe you're unable to push growth back above the historical rates seen in life science tools?
Jacob Thaysen
executiveYeah, on that, I'd like to stay cautious about making too many statements at this point. It's been 40 days since I started in this role, but I remain of the view that Illumina's growth potential is stronger than that of many other companies in life science tools, and I'll return with additional perspective once I'm prepared later in 2024, though I don't believe Illumina currently sits at the same level as many of those other firms, yet it's premature for me to offer definitive guidance, so, let's wait and see.
Rachel Vatnsdal
analystThanks a lot, and Jacob, welcome to Illumina — appreciate you fielding our questions. To start, I'd like to touch on Core Illumina margins and build on what was asked before. More precisely, the margin implied for the fourth quarter for Core Illumina appears to have come down, yet with the placement figure being lower, your mix ought to lean more heavily toward consumables than is usual in Q4. So, from a one-time standpoint, is there anything additional we ought to consider, or any other puts and takes tied to that implied margin for the fourth quarter?
Jacob Thaysen
executiveJoydeep, would you like to handle that?
Joydeep Goswami
executiveOkay, so Rachel, there are a few things to keep in mind here, correct? You're going to notice margins and operating margins coming down. From Q3 to Q4, we're looking at a step down in revenue. That's one part of it. The second part is that gross margins are being hit for a few reasons, right? First, whenever there's a drop in volume, you get less absorption of fixed costs, so that feeds into it. The second piece is around — yes, we are seeing some shift from instruments into consumables, but we're also seeing a reduction driven by the transition effects of NovaSeq 6000 consumables, which are highly profitable, so that's causing a bit of a gross margin decline. And then the third is that we have some components of strategic deal revenue coming in during Q4 versus Q3, and that is also dragging down our gross margin. So those three components are really what's hitting the gross margin piece. And on the operating margin side, I think we obviously are getting some of the benefits from the cost action that we saw, but we did have some movement of R&D specific timing investments that shifted from Q3 into Q4; so that is pushing up our Q4 operating expense a little bit compared to what we had in Q3.
Jacob Thaysen
executiveThanks to all of you. With the year wrapping up and 2024 getting underway, I'd like to restate the strong base we've got in place — both the infrastructure we've constructed and the sizable markets we cater to; it's obvious to me that a huge chance exists to generate value for our customers and partners around the globe, and naturally for our shareholders as well. Thanks once more. We can't wait to see you at the conferences and other events coming up. Thank you.
Operator
operatorThanks a lot. That brings today's call to a close. We appreciate everyone taking part. Have a great rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.